Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 5/20 | 0.48 |
| ▸ | CYP11B1 | P15538 | 5/20 | 0.48 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.48 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.31 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.31 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.31 |
| ▸ | GSK3A | P49840 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | KMO | O15229 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KDM4A | O75164 | 1/20 | 0.30 |
| ▸ | KDM5A | P29375 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5017939 | 0.90 | CYP19A1 (0.46) | CYP19A1CYP11B1CYP11B2F2RL1PDE4B | |
| SCHEMBL5026559 | 0.85 | CYP19A1 (0.44) | CYP19A1CYP11B1CYP11B2PDE4BKMO | |
| SCHEMBL5023375 | 0.83 | CYP17A1 (0.42) | CYP19A1CYP11B1CYP11B2F2RL1PDE4B | |
| SCHEMBL5017972 | 0.81 | CYP19A1 (0.51) | CYP19A1CYP11B1CYP11B2PDE4BTSHR | |
| SCHEMBL5022946 | 0.81 | CYP19A1 (0.45) | CYP19A1CYP11B1CYP11B2F2RL1PDE4B | |
| SCHEMBL5017981 | 0.81 | PDE4B (0.45) | CYP19A1CYP11B1CYP11B2F2RL1PDE4B | |
| SCHEMBL5026504 | 0.81 | CYP19A1 (0.42) | CYP19A1CYP11B1CYP11B2F2RL1PDE4B | |
| SCHEMBL5017933 | 0.80 | CYP19A1 (0.50) | CYP19A1CYP11B1CYP11B2F2RL1PDE4B | |
| SCHEMBL5023378 | 0.77 | F2RL1 (0.37) | CYP19A1CYP11B1CYP11B2F2RL1PDE4B | |
| SCHEMBL5022728 | 0.75 | PDE4A (0.51) | CYP19A1CYP11B1CYP11B2PDE4BSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1554262-B1 | NOVEL TRICYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLENMARK PHARMACEUTICALS LTD (IN) | 2007-12-05 | — | — | EP | claimed |
| US-7238725-B2 | Tricyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them | GLENMARK PHARMACEUTICALS LTD. (IN) | 2007-07-03 | — | — | US | claimed |
| US-20060178418-A1 | Novel tricyclic compounds useful for the treatment of inflammatory and allergic disorders:process for their preparation and pharmaceutical compositions containing them | GLENMARK PHARMACEUTICALS LTD. (IN) | 2006-08-10 | — | — | US | claimed |
| US-20080146810-A1 | NOVEL TRICYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLENMARK PHARMACEUTICALS S.A. (CH) | 2008-06-19 | — | — | US | disclosed |
| EP-1554262-B1 | NOVEL TRICYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLENMARK PHARMACEUTICALS LTD (IN) | 2007-12-05 | — | — | EP | disclosed |
| US-7238725-B2 | Tricyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them | GLENMARK PHARMACEUTICALS LTD. (IN) | 2007-07-03 | — | — | US | disclosed |
| US-20060178418-A1 | Novel tricyclic compounds useful for the treatment of inflammatory and allergic disorders:process for their preparation and pharmaceutical compositions containing them | GLENMARK PHARMACEUTICALS LTD. (IN) | 2006-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146810-A1 | NOVEL TRICYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LTC4S, TSLP, GPR119 | CYP19A1 248/4885CYP11B1 96/4885CYP11B2 105/4885 |
| US-20060178418-A1 | Novel tricyclic compounds useful for the treatment of inflammatory and allergic disorders:process for their preparation and pharmaceutical compositions containing them | LTC4S, TSLP, GPR119 | CYP19A1 248/4885CYP11B1 96/4885CYP11B2 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.